Robert A. Lenz
CIK: 0001992908
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (13 total)
- Aug 22, 2026NBP
NovaBridge Biosciences
Exercise(M)Direct17.2K shares- - Jun 3, 2026LBRX
LB PHARMACEUTICALS INC
Award(A)DirectStock Option (Right to Buy)
12.5K shares- - Mar 6, 2026LBRX
LB PHARMACEUTICALS INC
Award(A)DirectStock Option (Right to Buy)
20K shares- - Feb 18, 2025NMRA
Neumora Therapeutics, Inc.
Sale(S)Direct5.6K shares at avg. $1.67$9K - Feb 13, 2025NMRA
Neumora Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
502.9K shares- - Feb 13, 2025NMRA
Neumora Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
100K shares- - Feb 13, 2025NMRA
Neumora Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
502.9K shares- - Feb 13, 2025NMRA
Neumora Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
100K shares- - Oct 10, 2024NMRA
Neumora Therapeutics, Inc.
Sale(S)Direct8.3K shares at avg. $15.09$125K - Oct 9, 2024NMRA
Neumora Therapeutics, Inc.
Sale(S)Direct5.6K shares at avg. $15.01$84K - Sep 18, 2024NMRA
Neumora Therapeutics, Inc.
Sale(S)Direct10.7K shares at avg. $12.09$129K - Sep 17, 2024NMRA
Neumora Therapeutics, Inc.
Sale(S)Direct30.8K shares at avg. $11.81$364K - Sep 12, 2024NMRA
Neumora Therapeutics, Inc.
Sale(S)Direct32.9K shares at avg. $11.43$377K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 22, 2026 |  NBP NovaBridge Biosciences | Exercise(M) | 17,218 | - | $0 | Direct |
| Jun 3, 2026 |  LBRX LB PHARMACEUTICALS INC | Award(A) Stock Option (Right to Buy) | 12,500 | - | - | Direct |
| Mar 6, 2026 | LBRX LB PHARMACEUTICALS INC | Award(A) Stock Option (Right to Buy) | 20,000 | - | - | Direct |
| Feb 18, 2025 |  NMRA Neumora Therapeutics, Inc. | Sale(S) | 5,614 | $1.67 | $9,383 | Direct |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 502,934 | - | - | Direct |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 100,000 | - | - | Direct |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 502,934 | - | - | Direct |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 100,000 | - | - | Direct |
| Oct 10, 2024 | NMRA Neumora Therapeutics, Inc. | Sale(S) | 8,260 | $15.09 | $124,603 | Direct |
| Oct 9, 2024 | NMRA Neumora Therapeutics, Inc. | Sale(S) | 5,563 | $15.01 | $83,507 | Direct |
| Sep 18, 2024 | NMRA Neumora Therapeutics, Inc. | Sale(S) | 10,676 | $12.09 | $129,091 | Direct |
| Sep 17, 2024 | NMRA Neumora Therapeutics, Inc. | Sale(S) | 30,788 | $11.81 | $363,736 | Direct |
| Sep 12, 2024 | NMRA Neumora Therapeutics, Inc. | Sale(S) | 32,948 | $11.43 | $376,665 | Direct |
1-13 of 13 transactions
About Lenz Robert A.
Lenz Robert A. (SEC CIK 0001992908) files insider reports with the SEC as Director of NovaBridge Biosciences (NBP), Director of LB PHARMACEUTICALS INC (LBRX) and Head of R&D of Neumora Therapeutics, Inc. (NMRA).
Signal8 holds 10 ownership filings by Lenz Robert A. (2 Form 3, 8 Form 4), filed between Sep 16, 2024 and Aug 25, 2026. Those filings report 13 transactions, from Sep 12, 2024 to Aug 22, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Lenz Robert A.'s filings is in ROCKVILLE, MD.
Recent filings by Lenz Robert A.
- Aug 22, 2026: Option exercise of NBP shares (Form 4, code M).
- Jun 3, 2026: Grant or award of LBRX derivative securities (Form 4, code A).
- Mar 6, 2026: Grant or award of LBRX derivative securities (Form 4, code A).
- Feb 18, 2025: Open-market sale of NMRA shares (Form 4, code S).
- Feb 13, 2025: Disposition to issuer transactions of NMRA derivative securities (2 lines, Form 4, code D).
Other insiders filing for NovaBridge Biosciences (NBP)
- Silberstein Charles, Chief Financial Officer
- Woo Ian Ying, Director
- Dennis Phillip Andrew, Chief Medical Officer
- Cao Sean Wuxiong, Chief Bus. Development Officer
- Dewhurst Martin William, Director
- Xu Cong Claire, EVP, Clinical Development